N/A
Completed N=25
Intramuscular Heating Rates of a Chattanooga Intelect XT Therapeutic Ultrasound
Ultrasound Therapy; Complications
Source: ClinicalTrials.gov NCT03816709 ↗
Enrolled (actual)
25
Serious AEs
0.0%
Results posted
May 2021
Primary outcomePrimary: Heating Rate at 1 cm Depth — 6.49 degrees Celcius
Summary
The purpose of this study is to determine the rate of tissue temperature increase in the triceps surae during an ultrasound treatment using the Chattanooga Intelect Legend XT. The following parameters will be used: 3 MHz frequency, 1.0 W/cm2 intensity, 15 minute treatment time. Thermocouples will be inserted at 1.0, 1.75, and 2.5 cm depths to determine the heating rates. Most modality textbook recommendations for therapeutic ultrasound are based on studies performed with the Omnisound ultrasound machine. Previous research has shown variations in power output across manufacturers, producing differences in tissue temperature increases. No information has been published regarding the heating rates of the Chattanooga Intelect Legend XT machine for ultrasound treatments. By determining the heating rates for this machine, clinicians will be better able to utilize the Chattanooga Intelect Legend XT to help reach therapeutic goals.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Heating Rate at 1 cm Depth |
6.49 | — |
| PRIMARY Heating Rate at 1.75 cm Depth |
5.50 | — |
| PRIMARY Heating Rate at 2.5 cm Depth |
3.07 | — |
Eligibility Criteria
Inclusion Criteria
- males and females between the ages of 18 - 35 years old
- able to speak English
- have less than 1 cm of adipose over the left medial gastrocnemius muscle.
Exclusion Criteria
- any current lower extremity injury
- any lower extremity injuries within the last 6 months
- open wounds
- skin infections
- impaired circulation
- peripheral vascular disease
- deep vein thrombosis
- advanced arthritis
- poor thermal regulation
- anesthetic areas
- neoplasms/tumors
- thrombophlebitis
- closed infections
- any allergies or sensitivities to betadine
- any abnormalities observed in the medial gastrocnemius muscle determined by diagnostic ultrasound
- 1.0 cm or greater adipose over the left medial gastrocnemius muscle.
Data sourced from ClinicalTrials.gov (NCT03816709). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.